Welcome Guest  |  Register/Login  | 
Email: sales@marketreportsonline.com Call : + 1 888 391 5441
SEARCH:   

Anemia - Pipeline Review, Q4 2010

Published : 
No. of Pages : 129
  Buy Now  

Anemia - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Anemia Pipeline Review, Q4 2010”, provides an overview of the Anemia therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. “Anemia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Anemia.
- A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Anemia pipeline depth and focus of Anemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Anemia Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Anemia 12
Anemia Therapeutics under Development by Companies 14
Anemia Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Companies Involved in Anemia Therapeutics Development 26
Medgenics Inc. 26
Amgen Inc. 26
Eli Lilly and Company 27
GlaxoSmithKline plc 27
Rockwell Medical Technologies, Inc. 28
Lentigen Corporation 29
Par Pharmaceutical Companies, Inc. 29
3SBio Inc. 30
Evotec Aktiengesellschaft 30
HemoBioTech, Inc. 31
Ligand Pharmaceuticals Incorporated 31
Regeneron Pharmaceuticals, Inc. 32
ProMetic Life Sciences Inc. 32
Lipoxen PLC 33
Boryung Pharmaceutical Co., Ltd. 33
Hanall Pharmaceutical Co., Ltd. 35
Asan Medical Center 35
Acceleron Pharma, Inc. 36
Cadila Pharmaceuticals Ltd. 36
Xenon Pharmaceuticals Inc. 37
NormOxys, Inc. 37
Akebia Therapeutics, Inc. 38
NOXXON Pharma AG 38
Palkion, Inc. 39
Avesthagen Limited 39
Kyowa Hakko Kirin Pharma, Inc. 40
Mayo Clinic 40
Universities/Institutes Involved in Anemia Therapeutics Development 41
Anemia Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Combination Products 50
Assessment by Route of Administration 51
Assessment by Molecule Type 54
Late Stage Drug Profiles – Companies 57
Aranesp - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Cyclophosphamide + Campath IH + TBI + Allogenic Stem Cell Transplantation - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cytoxan + Campath IH + Total Body Irradiation + Allogeneic Stem Cell Transplantation - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Nascobal - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NESP - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
R744 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Recombinant Human Erythropoietin-Alpha - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Late Stage Drug Profiles – Universities/Institutes 67
Anti-thymocyte globulin + Busulfan + Cyclophosphamide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Anti-thymocyte globulin + Cyclophosphamide - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Anti-thymocyte globulin + Cyclophosphamide + Total body irradiation - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Anti-thymocyte globulin + Fludarabine phosphate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Antithymocyte globulin + Cyclosporin A - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Aranesp - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
azithromycin + sulphadoxine pyrimethamine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
cisplatin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Cyclophosphamide + Fludarabine + anti-thymocyte globulin + Total Body Irradiation + Bone Marrow Transplantation - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 78
Cyclophosphamide + Anti-thymocyte globulin + Bone marrow transplantation - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Cyclophosphamide + Cyclosporin A - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Cyclophosphamide + Fludarabine + Anti Thymocyte Globulin + Radiation Therapy + Stem Cell Transplantation - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Cyclophosphamide + Fludarabine + Antithymocyte Globulin + Total Body Irradiation + Stem Cell Transplantation - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Cyclophosphamide + Fludarabine + TMG + Stem Cell Transplantation - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Cytarabine + Daunorubicin + Zosuquidar Trihydrochloride - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Cytarabine+ Idarubicin +Etoposide+ Fludarabine +G-CSF - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 90
daunorubicin hydrochloride + zosuquidar trihydrochloride + cytarabine + filgrastim + sargramostim - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 92
Duroferon - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Epoetin Alfa - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Epoetin Alfa + Dexamethasone - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
epoetin alfa + filgrastim - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Epoetin Alfa + Radiation Therapy - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Erythropoiesis Stimulating Agent - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Ferinject - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Fludarabine + Busulfan + Alemtuzumab + Allogeneic Stem Cell Transplantation - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Folic Acid - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Hydroxyurea - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Iron-Sucrose - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
ITN + RDT + Amodiaquine + Artimisinin - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
ITN + RDT + Sulphadoxine + Pyrimethamine - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Mabthera - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Prednisolone + Mabthera - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Procrit - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
recombinant human erythropoietin, rhEpo - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Revlimid + Procrit - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Sulfadoxine + Pyrimethamine - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Tranexamic Acid - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Zosuquidar Trihydrochloride + Daunorubicin + Cytarabine - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Discontinued Products 119
Anemia - Featured News 120
Dec 07, 2010: Alder Reports Encouraging Phase II Study Data Of ALD518 In Non-Small Cell Lung Cancer 120
Nov 30, 2010: Avesthagen's AVDESP Completes Clinical Batch Manufacturing In Malaysia 120
Nov 04, 2010: Affymax And Takeda Announce Hematide Publication In The New England Journal Of Medicine 121
Jul 28, 2010: HemoBioTech Receives US Patent For HemoTech For Treatment Of Acute Blood Loss 122
Jul 19, 2010: Medgenics Announces Encouraging New Results From Phase I/II Trials To Treat Anaemia 122
Jun 29, 2010: Vifor Pharma's FERGI-COR Study Gives Positive Data Of Ferinject For Treating Anemia In Inflammatory Bowel Patients 123
Jun 22, 2010: Affymax Receives $30 Million Milestone Payments For Database Lock Of Phase 3 Clinical Trials For Hematide/Peginesatide 124
Jun 21, 2010: Affymax And Takeda Announce Phase III Trial Results Of Hematide For Treatment Of Anemia In Chronic Renal Failure Patients 124
Jun 16, 2010: Akebia Announces Positive Results From Phase Ib Study Of AKB-6548 127
Apr 22, 2010: Affymax Announces Self-Imposed Quiet Period As The Company Analyzes Phase 3 Results For Hematide/Peginesatide 127
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 129
Contact Us 129
Disclaimer 129

Anemia - Pipeline Review, Q4 2010

Published By: Global Markets Direct
 

How to Purchase


Purchase products from our site in 5 easy steps.  Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .


Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option
Get Email alerts about market research reports from industries and publishers of your interest:
© 2009 Market Research Reports. All Rights Reserved. Privacy Policy. Terms & Conditions